These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25893808)

  • 41. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
    Hao S; Bai O; Yuan J; Qureshi M; Xiang J
    Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells.
    Mogi S; Sakurai J; Kohsaka T; Enomoto S; Yagita H; Okumura K; Azuma M
    Immunology; 2000 Dec; 101(4):541-7. PubMed ID: 11122458
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma.
    Highton AJ; Kojarunchitt T; Girardin A; Hook S; Kemp RA
    Immunol Cell Biol; 2015 Aug; 93(7):634-40. PubMed ID: 25708538
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants.
    Ali OA; Verbeke C; Johnson C; Sands RW; Lewin SA; White D; Doherty E; Dranoff G; Mooney DJ
    Cancer Res; 2014 Mar; 74(6):1670-81. PubMed ID: 24480625
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells.
    Bak SP; Barnkob MS; Bai A; Higham EM; Wittrup KD; Chen J
    J Immunol; 2012 Aug; 189(4):1708-16. PubMed ID: 22798683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
    Lutz-Nicoladoni C; Wallner S; Stoitzner P; Pircher M; Gruber T; Wolf AM; Gastl G; Penninger JM; Baier G; Wolf D
    Immunol Cell Biol; 2012 Jan; 90(1):130-4. PubMed ID: 21383769
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
    Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas.
    Murphy KA; Lechner MG; Popescu FE; Bedi J; Decker SA; Hu P; Erickson JR; O'Sullivan MG; Swier L; Salazar AM; Olin MR; Epstein AL; Ohlfest JR
    Clin Cancer Res; 2012 Sep; 18(17):4657-68. PubMed ID: 22781551
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
    Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
    Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4(+) T-independent CTL responses.
    Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Chibbar R; Wei Y; Liu Q; Xiang J
    Vaccine; 2011 Apr; 29(19):3538-47. PubMed ID: 21406265
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.
    Sharma RK; Schabowsky RH; Srivastava AK; Elpek KG; Madireddi S; Zhao H; Zhong Z; Miller RW; Macleod KJ; Yolcu ES; Shirwan H
    Cancer Res; 2010 May; 70(10):3945-54. PubMed ID: 20406989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice.
    Wang LX; Li Y; Yang G; Pang PY; Haley D; Walker EB; Urba WJ; Hu HM
    Eur J Immunol; 2010 May; 40(5):1375-85. PubMed ID: 20186876
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
    Durgan K; Ali M; Warner P; Latchman YE
    Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel costimulatory molecule gene-modified leukemia cell-derived exosome enhances the anti-leukemia efficacy of DC vaccine in mouse models.
    Zhang D; Jiang Y; Wang M; Zhao J; Wan J; Li Z; Huang D; Yu J; Li J; Liu J; Huang F; Hao S
    Vaccine; 2024 Oct; 42(24):126097. PubMed ID: 38960787
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
    Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
    J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo.
    Dawicki W; Watts TH
    Eur J Immunol; 2004 Mar; 34(3):743-751. PubMed ID: 14991604
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
    J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge.
    Mazorra Z; Mesa C; Fernández A; Fernández LE
    Cancer Immunol Immunother; 2008 Dec; 57(12):1771-80. PubMed ID: 18351335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.